Beacon Investment Advisory Services Inc. Sells 137,722 Shares of Zoetis Inc. $ZTS

Beacon Investment Advisory Services Inc. lowered its position in Zoetis Inc. (NYSE:ZTS) by 98.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,269 shares of the company’s stock after selling 137,722 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Zoetis were worth $285,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Summit Place Financial Advisors LLC increased its stake in shares of Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after purchasing an additional 76 shares in the last quarter. First County Bank CT boosted its holdings in Zoetis by 5.4% in the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after buying an additional 79 shares during the period. CWA Asset Management Group LLC boosted its holdings in Zoetis by 1.1% in the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after buying an additional 80 shares during the period. Balefire LLC grew its stake in Zoetis by 3.5% in the 3rd quarter. Balefire LLC now owns 2,463 shares of the company’s stock valued at $360,000 after buying an additional 84 shares in the last quarter. Finally, Evergreen Capital Management LLC grew its stake in Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after buying an additional 85 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE:ZTS opened at $116.41 on Tuesday. The business’s 50-day moving average price is $123.23 and its two-hundred day moving average price is $128.79. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23. The stock has a market cap of $49.14 billion, a P/E ratio of 19.34, a PEG ratio of 1.73 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Wall Street Analyst Weigh In

Several research firms have issued reports on ZTS. UBS Group set a $136.00 target price on Zoetis in a research report on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.